VPRIV® (velaglucerase alfa) (Intravenous)

I. Length of Authorization

Coverage will be provided for 12 months and may be renewed.

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:
   - Vpriv 400 unit powder for injection: 18 vials per 14 days

B. Max Units (per dose and over time) [HCPC Unit]:
   - 72 billable units every 14 days

III. Initial Approval Criteria 1,9-13

Site of care specialty infusion program requirements are met (refer to Moda Site of Care Policy).

Coverage is provided in the following conditions:

- Patient is at least 4 years of age; AND

Universal Criteria

- Used as a single agent; AND

Type 1 Gaucher Disease † Φ

- Patient has a documented diagnosis of Type 1 Gaucher Disease confirmed by one of the following:
  - Significantly reduced or absent glucocerebrosidase enzyme activity as measured by a beta-glucosidase leukocyte (BGL) test
  - Detection of mutations in the glucocerebrosidase (GBA) gene; AND

- Adults only (i.e., patients at least 18 years or older) Patient's disease results in one or more of the following:
- Anemia \( i.e., \) hemoglobin less than or equal to 11 g/dL (women) or 12 g/dL (men) not attributed to iron, folic acid, or vitamin B12 deficiency
- Moderate to severe hepatomegaly (liver size 1.25 or more times normal) OR splenomegaly (spleen size 5 or more times normal)
- Skeletal disease (e.g., lesions, remodeling defects and/or deformity of long bones, osteopenia/osteoporosis, etc.)
- Symptomatic disease (e.g., bone pain, fatigue, dyspnea, angina, abdominal distension, diminished quality of life, etc.)
- Thrombocytopenia (platelet count less than or equal to 120,000/mm\(^3\))

† FDA Approved Indication(s); ‡ Compendia recommended Indication(s); ⊥ Orphan Drug

IV. Renewal Criteria \(^1\,\,^9\,-\,\,^{12}\)

Coverage can be renewed based on the following criteria:

- Patient continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III: AND
- Disease response with treatment as defined by one or more of the following (compared to pre-treatment baseline):
  - Improvement in symptoms (e.g., bone pain, fatigue, dyspnea, angina, abdominal distension, diminished quality of life, etc.)
  - Reduction in size of liver or spleen
  - Improvement in hemoglobin/anemia
  - Improvement in skeletal disease (e.g., increase in lumbar spine and/or femoral neck BMD, no bone crises or bone fractures, etc.)
  - Improvement in platelet counts: AND
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: severe hypersensitivity reactions, etc.

V. Dosage/Administration\(^1\)

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 1 Gaucher Disease</td>
<td>Administer up to 60 units/kg every other week as an intravenous infusion</td>
</tr>
</tbody>
</table>

VI. Billing Code/Availability Information

HCPCS Code:
- J3385 – Injection, velaglucerase alfa, 100 units: 1 billable unit = 100 units
VII. References


**Appendix 1 – Covered Diagnosis Codes**

<table>
<thead>
<tr>
<th>ICD-10</th>
<th>ICD-10 Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E75.22</td>
<td>Gaucher disease</td>
</tr>
</tbody>
</table>

**Appendix 2 – Centers for Medicare and Medicaid Services (CMS)**

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles may exist and compliance with these policies is required where applicable. They can be found at: [https://www.cms.gov/medicare-coverage-database/search.aspx](https://www.cms.gov/medicare-coverage-database/search.aspx). Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

<table>
<thead>
<tr>
<th>Jurisdiction</th>
<th>Applicable State/US Territory</th>
<th>Contractor</th>
</tr>
</thead>
<tbody>
<tr>
<td>E (1)</td>
<td>CA, HI, NV, AS, GU, CNMI</td>
<td>Noridian Healthcare Solutions, LLC</td>
</tr>
<tr>
<td>F (2 &amp; 3)</td>
<td>AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ</td>
<td>Noridian Healthcare Solutions, LLC</td>
</tr>
<tr>
<td>5</td>
<td>KS, NE, IA, MO</td>
<td>Wisconsin Physicians Service Insurance Corp (WPS)</td>
</tr>
<tr>
<td>6</td>
<td>MN, WI, IL</td>
<td>National Government Services, Inc. (NGS)</td>
</tr>
<tr>
<td>H (4 &amp; 7)</td>
<td>LA, AR, MS, TX, OK, CO, NM</td>
<td>Novitas Solutions, Inc.</td>
</tr>
<tr>
<td>8</td>
<td>MI, IN</td>
<td>Wisconsin Physicians Service Insurance Corp (WPS)</td>
</tr>
<tr>
<td>N (9)</td>
<td>FL, PR, VI</td>
<td>First Coast Service Options, Inc.</td>
</tr>
<tr>
<td>J (10)</td>
<td>TN, GA, AL</td>
<td>Palmetto GBA, LLC</td>
</tr>
<tr>
<td>M (11)</td>
<td>NC, SC, WV, VA (excluding below)</td>
<td>Palmetto GBA, LLC</td>
</tr>
<tr>
<td>L (12)</td>
<td>DE, MD, PA, NJ, DC (includes Arlington &amp; Fairfax counties and the city of Alexandria in VA)</td>
<td>Novitas Solutions, Inc.</td>
</tr>
<tr>
<td>K (13 &amp; 14)</td>
<td>NY, CT, MA, RI, VT, ME, NH</td>
<td>National Government Services, Inc. (NGS)</td>
</tr>
<tr>
<td>15</td>
<td>KY, OH</td>
<td>CGS Administrators, LLC</td>
</tr>
</tbody>
</table>